B+
Bull case
25%
Probability
Target price
$54.00
Analysis reference price unavailable
Analysis 2026-09-26 · RankAlpha Sentiment Codex
ALKS
AlkermesCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
50%
Probability
Target price
$43.00
Analysis reference price unavailable
Analysis 2026-09-26 · RankAlpha Sentiment Codex
B-
Bear case
25%
Probability
Target price
$31.00
Analysis reference price unavailable
Analysis 2026-09-26 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-09-26
Recent news sentiment (30D)
0.0
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+50.9
Score
AI commentary
The Phase 1b release was favorable in company framing, but the market did not sustain an advance: ALKS closed up 1.82% on September 21, then fell from $44.18 to the $40.85 September 25 anchor, a decline of about 7.5% historical closes. That sequence is not proof of a single cause. Analyst views are mixed rather than uniformly revised upward. Social coverage is absent; the zero-valued social, options, short-interest, and employee fields are missing-data placeholders, not neutral measurements.
RankAlpha Sentiment Codex - 2026-09-26
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31eventAlixorexton idiopathic-hypersomnia Phase 2 readoutHigh impact
Management expects topline results toward year-end 2026. A convincing placebo-controlled result could broaden the orexin portfolio opportunity; an equivocal result would weaken it [#SEC-8K-2026-07-28].
2026-12-31catalystCommercial sales and expense execution against 2026 guidanceMedium impact
Q2 proprietary-product sales were $411.7 million, but R&D and SG&A rose year over year. Alkermes retained its $1.73–$1.84 billion revenue and $370–$410 million adjusted-EBITDA ranges while lowering its GAAP earnings outlook. Delivery across LUMRYZ and the established portfolio, without further expense pressure, is the near-term test [#SEC-8K-2026-07-28].
2027-12-31catalystPlacebo-controlled ALKS 7290 ADHD Phase 2 dataHigh impact
The September 21 Phase 1b announcement reported dose-dependent improvements from baseline, but those endpoints were exploratory and the study was not powered to establish a treatment-placebo difference [#8-K-2026-09-21]. The enrolling Phase 2 trial is expected to produce data in 2027 and is the more decisive efficacy test SEC-filed company release.
Recommendation
N/A
No formal recommendation provided.
As of 2026-09-26 • Updated nightlySource: Internal modelMethodology